Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ:CVKD
RESEARCH TOOLSreports
Cadrenal Therapeutics, Inc. (CVKD) Stock Price & Analysis
48 Followers
CVKD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.36 - $3.14
Previous Close$0.41
Volume171.36K
Average Volume (3M)238.43K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$8.40M
Total Debt (Recent Filing)$21.35K
Price to Earnings (P/E)-1.2
Beta1.14
Next Earnings
Aug 08, 2024EPS Estimate
-$0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding16,008,469
10 Day Avg. Volume116,353
30 Day Avg. Volume238,431
Standard Deviation0.50
R-Squared0.02
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.90
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$3.50Price Target Upside751.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Cadrenal Therapeutics, Inc. News
PremiumCompany Announcements
Cadrenal Therapeutics Gains FDA Orphan Drug Status for Tecarfarin
PremiumCompany Announcements
Cadrenal Therapeutics Announces Key Executive AppointmentBulls Say, Bears Say
Bulls Say
Drug DevelopmentCadrenal received orphan drug designation for Tecarfarin, underscoring the potential for a new treatment option in the anticoagulant market.
Financial PerformanceCadrenal's recent financial results showed an EPS that exceeded expectations, signaling stronger financial health and potentially increasing investor confidence.
Regulatory MilestoneAnalyst confidence is growing in Cadrenal's prospects for FDA approval to include TTR as a key measure in clinical trials, which could be a significant step forward for the company.
Bears Say
EarningsCadrenal reported lower earnings per share than anticipated, missing both the initial estimate and consensus.
Funding RequirementsCadrenal needs to secure more capital to finance its upcoming Phase 3 clinical trial, which could strain the company's financial resources.
Shareholder RisksCadrenal's plan to acquire additional funds for its Phase 3 trial could lead to shareholder dilution.
---
Ownership Overview
46.47% Insiders
0.27% Mutual Funds
8.68% Other Institutional Investors
44.57% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CVKD FAQ
What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?
Cadrenal Therapeutics, Inc. lowest stock price was $0.36 and its highest was $3.14 in the past 12 months.
What is Cadrenal Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?
Cadrenal Therapeutics, Inc.’s upcoming earnings report date is Aug 08, 2024 which is in 82 days.
How were Cadrenal Therapeutics, Inc.’s earnings last quarter?
Cadrenal Therapeutics, Inc. released its earnings results on May 09, 2024. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.075 by -$0.025.
Is Cadrenal Therapeutics, Inc. overvalued?
According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Undervalued.
Does Cadrenal Therapeutics, Inc. pay dividends?
Cadrenal Therapeutics, Inc. does not currently pay dividends.
What is Cadrenal Therapeutics, Inc.’s EPS estimate?
Cadrenal Therapeutics, Inc.’s EPS estimate is -$0.09.
How many shares outstanding does Cadrenal Therapeutics, Inc. have?
Cadrenal Therapeutics, Inc. has 16,008,469 shares outstanding.
What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?
Cadrenal Therapeutics, Inc. reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.075. Following the earnings report the stock price went down -2.041%.
Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CVKD
---
Cadrenal Therapeutics, Inc. Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (751.58% Upside)
$3.50 (751.58% Upside)
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.05%
12-Months-Change
Fundamentals
Return on Equity
-94.50%
Trailing 12-Months
Asset Growth
57.26%
Trailing 12-Months
Company Description
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
---
CVKD Stock 12 Month Forecast
Average Price Target
$3.50
▲(751.58% Upside)
Technical Analysis
Best Analysts Covering CVKD
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-14.83%
reiterated a buy rating last month
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -14.83% per trade.
---